InhA-IN-7, with the CAS number 952588-17-9, is a small molecule inhibitor that targets the InhA enzyme, which is crucial in the fatty acid synthesis pathway of Mycobacterium tuberculosis. This compound is part of a class of antitubercular agents that aim to combat tuberculosis by disrupting the synthesis of mycolic acids, essential components of the bacterial cell wall. InhA-IN-7 exhibits characteristics typical of enzyme inhibitors, including high specificity for its target and the potential for low toxicity to human cells. Its structure likely includes functional groups that facilitate binding to the active site of InhA, enhancing its efficacy. The compound is of particular interest in medicinal chemistry and pharmaceutical development due to its potential role in treating drug-resistant strains of tuberculosis. Research into its pharmacokinetics, bioavailability, and overall therapeutic profile is essential for understanding its viability as a treatment option.

InhA-IN-7

952588-17-9: InhA-IN-7, with the CAS number 952588-17-9, is a small molecule inhibitor that targets the InhA enzyme, which is crucial in the fatty acid synthesis pathway of Mycobacterium tuberculosis. This compound is part of a class of antitubercular agents that aim to combat tuberculosis by disrupting the synthesis of mycolic acids, essential components of the bacterial cell wall. InhA-IN-7 exhibits characteristics typical of enzyme inhibitors, including high specificity for its target and the potential for low toxicity to human cells. Its structure likely includes functional groups that facilitate binding to the active site of InhA, enhancing its efficacy. The compound is of particular interest in medicinal chemistry and pharmaceutical development due to its potential role in treating drug-resistant strains of tuberculosis. Research into its pharmacokinetics, bioavailability, and overall therapeutic profile is essential for understanding its viability as a treatment option.

<p>InhA-IN-7 (Compound 11), a derivative of Triclocan, shows inhibitory activity against enoyl-acyl carrier protein reductase (InhA) with an IC50 of 96 nM. It effectively inhibits the proliferation of both wildtype and mutant strains of Mycobacterium tuberculosis, exhibiting minimum inhibitory concentrations (MICs) ranging from 19 to 75 μM [1].</p>

CAS 952588-17-9

InhA-IN-7

InhA-IN-7

Ref: TM-T86721